Contrast injector systems are medical devices that use contrast media to enhance the visibility of complex body structures such as body fluids, tissues, arteries and veins. The diagnosis is conducted with the help of many imaging procedures such as computed tomography (CT), magnetic resonance imaging (MRI) and angiography.
The contrast injector system market was valued at $554.38 million in 2016 and is expected to reach $954.62 million by 2023, registering a CAGR of 8.1 percent during the forecast period, according to Allied Market Research.
“The rise in geriatric population coupled with rapid rise in chronic diseases as well as the demand for early and minimal-invasive diagnosis are the key factors that drive the growth of the contrast injector systems market,” according to Allied Market Research. “However, the high cost of contrast injector systems and the risks associated with the use of contrast media in the injector system is projected to impede the market growth. Moreover, the increase in health care expenditure and the emergence of complex diseases in emerging economies are expected to create lucrative opportunities for key market players.”
Researchers echo the forecast for continued growth.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a CAGR of 5.8 percent, according to a report by Grand View Research Inc.
“Rising demand for minimally invasive surgical procedures is a major factor expected to boost the market during the forecast period,” according to Grand View Research. “These devices assist surgeons in accurate insertion of contrast agents with reduced human errors, thus increasing the accuracy and efficiency of surgical procedures. They play a crucial role in Intraoperative Computed Tomography (iCT), Intraoperative Magnetic Resonance Imaging (iMRI), and interventional cardiology. Availability of advanced injector systems for diagnosis and intraoperative imaging has boosted adoption of these systems. For instance, Medrad Stellant CT injection system integrated with Certegra Workstation provides high efficiency and accuracy in CT imaging.”
“Technological advancements, such as automated contrast media injectors and double-head injectors, are also among major factors supporting the growth of the market,” the report added. “Automated contrast media injectors provide improved patient safety, accuracy and enhance image quality. Also, double-head injectors allow a large and rapid initial bolus of contrast, which is required in several imaging procedures. For instance, in cardiac CT, a fast injection is required for imaging of both sides of the ventricular septum to identify septal thickness, shunts and enlarged ventricles. Delivery of contrast media is more efficient and controlled with a dual-head injector.”
As estimated in a Zion Market Research report, the global contrast injector market stood at $660 million in 2016.
Witnessing a tremendous rise during the period from 2017 to 2022, the revenue in this contrast injector market is expected to reach $889.3 million by the end of the forecast period. The main products available in this contrast injector market are injector systems, consumables and accessories. Among the three, the demand for injector systems is relatively higher and the trend is anticipated to remain so over the next few years, notes the research report.
